CORDA Investment Management LLC. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 171,748 shares of the company’s stock after selling 3,484 shares during the period. Johnson & Johnson accounts for 2.6% of CORDA Investment Management LLC.’s portfolio, making the stock its 16th largest position. CORDA Investment Management LLC.’s holdings in Johnson & Johnson were worth $28,226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in JNJ. Norges Bank bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $4,370,566,000. Sanders Capital LLC bought a new position in Johnson & Johnson in the fourth quarter valued at approximately $1,126,076,000. Morgan Stanley boosted its position in shares of Johnson & Johnson by 7.3% during the fourth quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock worth $3,794,594,000 after purchasing an additional 1,638,263 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock worth $5,029,590,000 after purchasing an additional 1,628,229 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Johnson & Johnson by 0.7% during the first quarter. BlackRock Inc. now owns 189,690,998 shares of the company’s stock worth $31,175,717,000 after purchasing an additional 1,379,656 shares in the last quarter. 66.74% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently weighed in on the stock. Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley assumed coverage on shares of Johnson & Johnson in a research report on Friday, May 28th. They set an “overweight” rating and a $187.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $182.45.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Monday, April 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $0.25. The firm had revenue of $22.30 billion for the quarter, compared to analyst estimates of $22 billion. Johnson & Johnson had a net margin of 17.95% and a return on equity of 34.62%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.30 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 9.51 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 8th. Stockholders of record on Tuesday, May 25th were paid a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, May 24th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.01. This represents a $4.24 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is currently 52.80%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.